Trulicity (Eli Lilly) is expected to face US biosimilar competition from 2027. Lilly 10-K: US compound patent and data protection end 2027.
Trulicity's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Trulicity was selected for the Medicare Drug Price Negotiation Program. CMS is negotiating its Medicare price now; the price takes effect in 2028 and is due to be published by 30 November 2026. US biosimilars are due by then. For the 25 drugs negotiated so far, Medicare prices came in 38% to 85% below list price. Those discounts are measured before the rebates drugmakers already pay and apply to Medicare only.
Trulicity is 6.6% of Eli Lilly's 2025 revenue ($4.3B of $65.2B). With Mounjaro, the drugs tracked here add up to 42% of Eli Lilly's revenue losing US exclusivity by 2036.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Trulicity is highlighted.